Graves' ophthalmopathy. Pathogenesis, diagnosis and therapy;Endokrine Orbitopathie. Pathophysiologie, Diagnostik und Therapie

Medizinische Welt

Volumn 48, Issue 6, 1997, Pages 230-238

  Heufelder, Armin E ^a,b   Hofbauer, L C ^a   Schworm, H D ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

diagnosis; Graves' disease; Graves' ophthalmopathy; pathogenesis; therapy; thyroid associated ophthalmopathy

Indexed keywords

GLUCOCORTICOID;

CLINICAL FEATURE; EYE DISEASE; GRAVES DISEASE; HUMAN; PATHOGENESIS; REVIEW;

EID: 0030737762     PISSN: 00258512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Antonelli A, Saracino A, Alberti B, Canapicchi R et al. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. Acta Endocrinol (Copenh) 1992; 126: 13-23.
2. Bahn RS, Heufelder AE. Mechanisms of disease: pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993; 329: 1468-75.
3. Bartalena L, Marcocci C, Bogazzi F et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radio-iodine therapy for hyperthyroidism. N Engl J Med 1989; 321: 1349-52.
4. Barth A, Probst P, Bürgi H. Identification of a subgroup of Graves' disease patients at higher risk for severe Graves' ophthalmopathy after radioiodine. J Endocrinol Invest 1994; 14: 209-12.
5. Beyer-Machule C-K. Surgical treatment of eye lid retractions. Dev Ophthalmol 1989; 20: 199-212.
6. Boergen KP. Ophthalmologische Befunde. In: Lund O-E, Waubke TN (Hrsg) Auge und Allgemeinleiden - Der Augenarzt als Konsiliarius. Enke Verlag, Stuttgart 1989: 140-50.
7. Boergen KP. Surgical repair of motility impairment in Graves' orbitopathy. Dev Ophthalmol 1989; 20: 159-68.
8. Boergen KP. Augenmuskelkorrekturen bei endokriner Orbitopathie. Akt Endokr Stoffw 1989; 10: 176-9.
9. Boergen KP. Schieloperation in Tropfanasthesie bei endokriner Orbitopathie. Zeitschr. prakt. Augenheilkd. 1993; 14: 301-5.
10. Boergen KP. Augenmuskelveränderungen und ihre Folgen bei endokriner Orbitopathie. Zeitschr prakt Augenheilkd 1993; 14: 351-6.
11. Boergen KP, Pickardt CR. Neueinteilung der Symptome der endokrinen Orbitopathie. Med Welt 1991; 42: 72-6.
12. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1995; 14: 747-93.
13. DeGroot LJ, Gorman CA, Pinchera A et al. Therapeutic controversies: Radiation and Graves' ophthalmopathy. J Clin Endocrinol Metab 1995; 80: 339-49.
14. Fatourechi V, Pajouhi M, Fransway AF. Dermopathy of Graves' disease (pretibial myxedema). Medicine 1994; 73: 1-7.
15. Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission of medical therapy for Graves' disease. J Clin Endocrinol Metab 1994; 78: 98-103.
16. Fernandez-Sanchez JR, Rosell Pradas J, Carazo Martinez O et al. Graves' ophthalmopathy after subtotal thyroidectomy and radioiodine therapy. Br J Surg 1993; 80: 1134-6.
17. Gamstedt A, Wadman B, Karlsson A, Methimazole but not betamethasone prevents 131I-treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease. J Clin Endocrinol Metab 1986; 62: 773-7.
18. Gamstedt A, Karlsson A. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy. J Clin Endocrinol Metab 1991; 73: 125-31.
19. Gorman CA, Heufelder AE, Bartley GBB. Ophthalmopathy. In: Endocrinology (Leslie deGroot ed.) Vol. I-III; 3rd edition, WB Saunders Company. Philadelphia 1995; 712-25.
20. Heufelder AE, Dutton CM, Sarkar G et al. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy. Thyroid 1993; 3: 297-300.
21. Heufelder AE, Bahn RS. Soluble intercellular adhesion molecule-1 (ICAM-1) sera of patients with Graves' ophthalmopathy and thyroid diseases. Clin. exp. Immunol. 1993; 92: 296-302.
22. Heufelder AE, Bahn RS. Detection and localization of cytokine immunoreactivity in retroocular connective tissue in Graves' ophthalmopathy. Eur. J. Clin. Invest. 1993; 23: 10-7.
23. Heufelder AE, Bahn RS. Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves' ophthalmopathy. Clin. exp. Immunol. 1993; 91: 381-9.
24. Heufelder AE, Bahn RS. Stimulation of human retroocular fibroblast proliferation by paracrine/autocrine factors and its antagonism by glucocorticoid receptor agonists. Invest Ophthalmol Vis Sci 1994; 35: 120-7.
25. Heufelder AE. Pathogenesis of Graves' ophthalmopathy: recent controversies and progress. Europ J Endocrinol 1995; 132: 532-41.
26. Heufelder AE, Herterich S, Ernst G et al. Analysis of retroorbital T cell antigen receptor variable region gene usage in patients with Graves' ophthalmopathy. Eur J Endocrinol 1995; 132: 266-77.
27. Heufelder AE, Bahn RS, Scriba PC. Analysis of T-cell antigen receptor variable region gene usage in patients with thyroid-related pretibial dermopathy. J Invest Dermatol 1995; 105: 372-8.
28. Heufelder AE. Involvement of the orbital fibroblast and TSH receptor in the pathogenesis of Graves' ophthalmopathy. Thyroid 1995; 5: 331-40.
29. Heufelder AE. Fortschritte in der Pathogenese und Therapie des Morbus Basedow. Der Nuklearmediziner 1995; 18: 153-62.
30. Joint Committee of European, Japanese, Asia-Oceanian, Latin American and American Thyroid Association: Classification of eye changes of Graves' disease. Thyroid 1992; 2: 235-6.
31. Kendall-Taylor P, Crombie AL, Perros P High-dose intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy. Br Med J 1988; 297: 1574-8.
32. Kung AWC, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 1994; 79: 542-6.
33. Marcocct C, Bartalena L, Bogazzi FA et al. Orbital radiotherapy combined with systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a randomized study. J Endocrinol Invest 1991; 14: 853-60.
34. Paschke R, Metcalfe A, Alcade L, Vassart G, Weetman A, Ludgate M. Presence of nonfunctional thyrotropin receptor variant transcripts in retroocular and other tissues. J Clin Endocrinol Metab 1994; 79: 1234-8.
35. Prummel MF, Wiersinga WM, Mounts MP. Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinol 1989; 121 (Suppl. 2): 185-9.
36. Prummel MF, Wiersinga WM, Mourits MP et al. Influence of abnormal thyroid function on the severity of accompanying Graves' ophthalmopathy Arch Int Med 1990; 150: 1098-1101.
37. Prummel MF, Mourits MP, Berghout A et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1991; 321: 1353-9.
38. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. J Am Med Assoc 1993; 269: 479-82.
39. Prummel MF, Mourits MP, Blank L et al. Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993; 342: 949-54.
40. Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 1989; 87: 70-3.
41. Tallstedt L, Lundell G, Tørring O et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992; 326: 1733-8.
42. Tallstedt L, Lundell G, Blomgren H et al. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994; 130: 494-7.
43. Weetman AP. Thyroid-associated eye disease: pathophysiology. Lancet 1993; 338: 25-32.
44. Werner SC. Modification of the classification of the eye changes of Graves' disease. Am J Ophthalmol 1977; 83: 725-7.